BridgeBio Pharma (BBIO) Revenue & Revenue Breakdown
BridgeBio Pharma Revenue Highlights
Latest Revenue (Y)
$221.90M
Latest Revenue (Q)
$2.17M
Main Segment (Y)
License
Main Geography (Y)
License
BridgeBio Pharma Revenue by Period
BridgeBio Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $221.90M | 2285.27% |
| 2023-12-31 | $9.30M | -88.02% |
| 2022-12-31 | $77.65M | 11.38% |
| 2021-12-31 | $69.72M | 745.14% |
| 2020-12-31 | $8.25M | -79.66% |
| 2019-12-31 | $40.56M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
BridgeBio Pharma generated $221.90M in revenue during NA 2024, up 2285.27% compared to the previous quarter, and up 547.10% compared to the same period a year ago.
BridgeBio Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $2.17M | -98.97% |
| 2024-03-31 | $211.12M | 11998.57% |
| 2023-12-31 | $1.75M | -57.35% |
| 2023-09-30 | $4.09M | 149.30% |
| 2023-06-30 | $1.64M | -10.13% |
| 2023-03-31 | $1.83M | -2.35% |
| 2022-12-31 | $1.87M | 453.25% |
| 2022-09-30 | $338.00K | -99.54% |
| 2022-06-30 | $73.75M | 4253.36% |
| 2022-03-31 | $1.69M | -86.85% |
| 2021-12-31 | $12.89M | 449.74% |
| 2021-09-30 | $2.34M | -95.66% |
| 2021-06-30 | $54.02M | 11593.51% |
| 2021-03-31 | $462.00K | 278.69% |
| 2020-12-31 | $122.00K | -98.50% |
| 2020-09-30 | $8.13M | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $13.82M | -48.32% |
| 2019-09-30 | $26.74M | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
BridgeBio Pharma generated $2.17M in revenue during Q2 2024, up -98.97% compared to the previous quarter, and up 118.73% compared to the same period a year ago.
BridgeBio Pharma Revenue Breakdown
BridgeBio Pharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 | Dec 19 |
|---|---|---|
| License | $8.00M | $13.80M |
BridgeBio Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 20: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Sep 20 |
|---|---|---|---|---|---|---|---|
| License and Service | $1.83M | $338.00K | $73.75M | - | - | - | - |
| Product | - | - | - | $1.46M | $759.00K | $987.00K | - |
| License | - | - | - | $235.00K | $1.58M | $8.00M | - |
BridgeBio Pharma's latest quarterly revenue breakdown by segment (product or service), as of Mar 23: License and Service (100.00%).
BridgeBio Pharma Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 19 |
|---|---|
| License | $13.80M |
BridgeBio Pharma's latest annual revenue breakdown by geography, as of Dec 19: License (100.00%).
Quarterly Revenue by Country
| Country | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Sep 20 |
|---|---|---|---|---|---|---|---|
| License and Service | $1.83M | $338.00K | $73.75M | - | - | - | - |
| Product | - | - | - | $1.46M | $759.00K | $987.00K | - |
| License | - | - | - | $235.00K | $1.58M | $8.00M | - |
BridgeBio Pharma's latest quarterly revenue breakdown by geography, as of Mar 23: License and Service (100.00%).
BridgeBio Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTCT | PTC Therapeutics | $806.78M | $135.42M |
| APLS | Apellis Pharmaceuticals | $709.95M | $176.57M |
| BPMC | Blueprint Medicines | $508.82M | $128.18M |
| KRYS | Krystal Biotech | $290.51M | $83.84M |
| BBIO | BridgeBio Pharma | $221.90M | $2.17M |
| MDGL | Madrigal Pharmaceuticals | $180.13M | $62.17M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
| AMLX | Amylyx Pharmaceuticals | $87.37M | $416.00K |
| XFOR | X4 Pharmaceuticals | $2.56M | $560.00K |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| TERN | Terns Pharmaceuticals | - | - |